Indoco Remedies Ltd.

₹213.75

-6.9 (-3.1%)

INDOCO Share Price

Pharmaceuticals & Biotechnology

As on October 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 1,976.08 Cr

P/E Ratio-20.74

Dividend Yield0.05 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	221.2	Bearish
10-DMA	229.51	Bearish
20-DMA	237.05	Bearish
50-DMA	241.54	Bearish
100-DMA	237.44	Bearish
200-DMA	222.34	Bearish

Historical Performance

1 Year

-21.8%

3 Years

-33.4%

5 Years

-52.3%

10 Years

-24.7%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	18,453	16,649	18,173	16,686	15,408
Total Expenditure	17,081	15,657	15,809	13,826	12,145
Other Income	80	55	187	26	34
Operating Profit	1,451	1,047	2,551	2,887	3,297
Interest	1,222	662	390	253	141
Depreciation	1,265	1,138	919	706	790
Profit Before Tax	-1,065	-744	1,358	1,928	2,366
Consolidated Net Profit	-951	-737	985	1,423	1,548
Adjusted EPS	-10	-8	11	15	17

Compounded Sales Growth

10 Years:12.9

5 Years:8.2

3 Years:2

TTM:2.1

Compounded Profit Growth

10 Years:-16.6

5 Years:-18.7

3 Years:-25.4

TTM:5.2

Stock Price CAGR

10 Years:-2.8

5 Years:-14.4

3 Years:-12.7

TTM:-22.4

Return on Equity

10 Years:8.4

5 Years:16.8

3 Years:10.7

last year:-10.3

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	185	184	184	184	184
Total Reserves	9,144	9,978	10,879	10,092	8,862
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	6,086	6,035	4,219	2,054	1,566
Other Current Liabilities	3,231	1,927	1,498	1,321	1,396
Short Term Borrowings	3,740	3,620	2,605	1,195	1,037
Total Liabilities	26,026	24,304	21,779	17,145	15,794
Capital Work in Progress	283	2,761	1,029	554	528
Long Term Loans & Advances	1,017	1,028	1,025	491	337
Currents Investments	---	---	72	10	---
Short Term Loans and Advances	2,050	1,675	1,548	1,584	2,048
Total Current Assets	11,793	10,018	9,878	8,698	8,669
Total Assets	26,026	24,304	21,779	17,145	15,794
Adjusted Book Value	101	110	120	112	98

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a low PE of -20.74, which may indicate undervaluation or subdued growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -12.9%, indicating poor shareholder returns.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹1451 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹18453 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 776566.8

No. of Shares: 3633 (Approx)

Performance:-22.3%

-223433.2

NIFTY Performance: -12.9%

1 day Top Gainers